OM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OM

Mkt Cap

$74.2M

Volume

65.08K

Next Earnings

November 9th

Loading chart

OM

OMOutset Medical, Inc. Common Stock

OM

Pay with—

Available Balance0.00

OM

Mkt Cap

$76.7M

Volume

65.08K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Here's Why You Should Retain DaVita Stock in Your Portfolio for NowDaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market.Zacks Investment Research · Oct 9, 2026

Reasons to Retain Hims & Hers Stock in Your Portfolio for NowHims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 8, 2026

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.Zacks Investment Research · Sep 3, 2026

Stock Market Today: S&P 500, Nasdaq Futures Drop Despite Senate Passing Resolution To Reopen Government—Nvidia, Paramount Skydance In Focus (UPDATED)U.S. stock futures fell on Tuesday after the Senate passed a resolution to reopen the government. Market attention was focused on several company earnings reports and potential Federal Reserve interest rate cuts.Benzinga · Nov 11, 2025

Outset Medical to Present at RBC Global Healthcare ConferenceOutset Medical, a medical technology company, announced that members of its management team will participate in the RBC Capital Markets Global Health Care conference on May 20, 2025. The company's Tablo Hemodialysis System, which is FDA-cleared for use from the hospital to the home, represents a significant technological advancement in the dialysis industry.GlobeNewswire Inc. · May 9, 2025

Outset Medical to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025Outset Medical, a medical technology company, announced a one-for-fifteen reverse stock split. The company also plans to release its Q1 2025 financial results and host a conference call to discuss the results.GlobeNewswire Inc. · Apr 16, 2025

Outset Medical: Profitability Path BrightensOutset Medical reported strong Q4 earnings, with revenue and adjusted EPS beating analyst estimates. The company saw improved gross margins and reduced operating expenses, signaling progress towards profitability. Outset remains optimistic about future growth, projecting revenue of $115-$125 million by 2025.The Motley Fool · Feb 19, 2025

Kuehn Law Encourages Investors of Outset Medical, Inc. to Contact Law FirmKuehn Law is investigating Outset Medical, Inc. (OM) for potential breach of fiduciary duties, alleging the company misrepresented or failed to disclose information about its Tablo products and their regulatory approval status.GlobeNewswire Inc. · Feb 6, 2025

Outset Medical to Present at the 2024 Stifel Healthcare ConferenceOutset Medical, a medical technology company, announced that members of its management team will present at the 2024 Stifel Healthcare conference on November 19, 2024. The company's Tablo Hemodialysis System, which is FDA-cleared for use from the hospital to the home, represents a significant technological advancement in the dialysis industry.GlobeNewswire Inc. · Nov 15, 2024

Outset Partners with User Interviews for Qualitative ResearchOutset, an AI-moderated research platform, has partnered with User Interviews, a leader in research participant recruitment, to provide businesses and B2B researchers with a streamlined, scalable, and efficient way to conduct in-depth qualitative research.GlobeNewswire Inc. · Oct 31, 2024

to start trading

OM

OMOutset Medical, Inc. Common Stock

OM

Pay with—

Available Balance0.00

Your PositionYou don't own any OM yet.

Related Tickers

Earnings